{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:33:27Z","timestamp":1787416407453,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xphs.2025.104006","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T04:00:07Z","timestamp":1758686407000},"page":"104006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and evaluation of gluconic acid-targeted liposomal doxorubicin for enhanced anti-tumor activity in colon cancer"],"prefix":"10.1016","volume":"114","author":[{"given":"Saba","family":"Dadpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mashreghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Shahraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Mehrabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-3615","authenticated-orcid":false,"given":"Seyedeh Alia","family":"Moosavian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3908-6828","authenticated-orcid":false,"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.104006_bib0001","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.semcancer.2019.09.025","article-title":"Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy","volume":"69","author":"Moosavian","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.xphs.2025.104006_bib0002","first-page":"448","article-title":"Aptamer-functionalized liposomes for targeted cancer therapy","author":"Moosavian","year":"2019","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.xphs.2025.104006_bib0003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2013the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Rel"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.104006_bib0004","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J Control Rel"},{"issue":"11","key":"10.1016\/j.xphs.2025.104006_bib0005","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/bies.201300084","article-title":"The Warburg effect then and now: from cancer to inflammatory diseases","volume":"35","author":"Palsson-McDermott","year":"2013","journal-title":"BioEssays"},{"key":"10.1016\/j.xphs.2025.104006_bib0006","series-title":"Smart Nanocontainers","first-page":"251","article-title":"Chapter 15 - smart nanocarriers in glucose transporters-targeted delivery of anticancer drugs","author":"Dastghaib","year":"2020"},{"key":"10.1016\/j.xphs.2025.104006_bib0007","volume":"33","author":"Park","year":"2022"},{"issue":"2","key":"10.1016\/j.xphs.2025.104006_bib0008","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2009.09.020","article-title":"Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals","volume":"141","author":"Ying","year":"2010","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.xphs.2025.104006_bib0009","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-12-2072","article-title":"Targeted cancer therapy with a 2-deoxyglucose\u2013Based adriamycin complex","volume":"73","author":"Cao","year":"2013","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.xphs.2025.104006_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164184","article-title":"Glucose transporters as a target for anticancer therapy","volume":"13","author":"Pliszka","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xphs.2025.104006_bib0011","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jconrel.2019.11.031","article-title":"Photothermally triggered cytosolic drug delivery of glucose functionalized polydopamine nanoparticles in response to tumor microenvironment for the GLUT1-targeting chemo-phototherapy","volume":"317","author":"Li","year":"2020","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.xphs.2025.104006_bib0012","doi-asserted-by":"crossref","first-page":"11788","DOI":"10.18632\/oncotarget.14352","article-title":"GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.xphs.2025.104006_bib0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E","article-title":"GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis","volume":"83","author":"Haber","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.xphs.2025.104006_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.chemphyslip.2015.03.003","article-title":"p-aminophenyl-\u03b1-d-mannopyranoside engineered lipidic nanoparticles for effective delivery of docetaxel to brain","volume":"188","author":"Singh","year":"2015","journal-title":"Chem Phys Lipids"},{"issue":"4","key":"10.1016\/j.xphs.2025.104006_bib0015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00253-007-0851-x","article-title":"Biotechnological production of gluconic acid: future implications","volume":"75","author":"Singh","year":"2007","journal-title":"Appl, Microbiol, Biotechnol"},{"issue":"10","key":"10.1016\/j.xphs.2025.104006_bib0016","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93098","article-title":"Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression","volume":"2","author":"Thackeray","year":"2017","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.xphs.2025.104006_bib0017","first-page":"2054","article-title":"5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells. Artificial cells","volume":"46","author":"Moosavian","year":"2018","journal-title":"Nanomed Biotechnol"},{"issue":"2","key":"10.1016\/j.xphs.2025.104006_bib0018","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijpharm.2013.10.018","article-title":"Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas","volume":"458","author":"Amin","year":"2013","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2025.104006_bib0019","doi-asserted-by":"crossref","first-page":"e3116","DOI":"10.1002\/btpr.3116","article-title":"Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model","volume":"37","author":"Mashreghi","year":"2021","journal-title":"Biotechnol, Prog"},{"issue":"1","key":"10.1016\/j.xphs.2025.104006_bib0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12645-023-00236-0","article-title":"CD44-specific short peptide A6 boosts cellular uptake and anticancer efficacy of PEGylated liposomal doxorubicin in vitro and in vivo","volume":"14","author":"Yazdian-Robati","year":"2023","journal-title":"Cancer Nanotechnol"},{"key":"10.1016\/j.xphs.2025.104006_bib0021","article-title":"Preparation of AS1411 aptamer-modified PEGylated liposomal doxorubicin and evaluation of its anti-cancer effects in vitro and in vivo","volume":"81","author":"Iman","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"issue":"23","key":"10.1016\/j.xphs.2025.104006_bib0022","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1002\/anie.200900111","article-title":"Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery","volume":"48","author":"Huang","year":"2009","journal-title":"Angew Chem (Int Engl)"},{"issue":"5","key":"10.1016\/j.xphs.2025.104006_bib0023","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/nl900031y","article-title":"Mediating tumor targeting efficiency of nanoparticles through design","volume":"9","author":"Perrault","year":"2009","journal-title":"Nano Lett"},{"key":"10.1016\/j.xphs.2025.104006_bib0024","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.colsurfb.2015.12.009","article-title":"Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model","volume":"139","author":"Moosavian","year":"2016","journal-title":"Colloid Surf B: Biointerfac"},{"issue":"1","key":"10.1016\/j.xphs.2025.104006_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s11671-020-03334-9","article-title":"Anti-epcam aptamer (Syl3c)-functionalized liposome for targeted delivery of doxorubicin: in vitro and In vivo antitumor studies in mice bearing C26 colon carcinoma","volume":"15","author":"Mashreghi","year":"2020","journal-title":"Nanoscale Res Lett"},{"issue":"6","key":"10.1016\/j.xphs.2025.104006_bib0026","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbamem.2006.04.015","article-title":"Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature","volume":"1758","author":"Iwasa","year":"2006","journal-title":"Biochim Biophys Acta (BBA) - Biomembr"},{"issue":"13\u201314","key":"10.1016\/j.xphs.2025.104006_bib0027","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.addr.2013.09.004","article-title":"Biophysics of cell membrane lipids in cancer drug resistance: implications for drug transport and drug delivery with nanoparticles","volume":"65","author":"Peetla","year":"2013","journal-title":"Adv, Drug Deliv, Rev"},{"key":"10.1016\/j.xphs.2025.104006_bib0028","doi-asserted-by":"crossref","unstructured":"Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. 2013;65(2):157\u201370.","DOI":"10.1111\/j.2042-7158.2012.01567.x"},{"issue":"2","key":"10.1016\/j.xphs.2025.104006_bib0029","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol, Rev"},{"issue":"1","key":"10.1016\/j.xphs.2025.104006_bib0030","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijpharm.2013.06.017","article-title":"Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment","volume":"454","author":"Duong","year":"2013","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2025.104006_bib0031","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0163-7827(03)00032-8","article-title":"Ligand-targeted liposomal anticancer drugs","volume":"42","author":"Sapra","year":"2003","journal-title":"Prog, Lipid Res"},{"issue":"4","key":"10.1016\/j.xphs.2025.104006_bib0032","first-page":"1172","article-title":"Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery","volume":"8","author":"Park","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.xphs.2025.104006_bib0033","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.xphs.2025.104006_bib0034","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"10.1016\/j.xphs.2025.104006_bib0035","first-page":"6551","article-title":"Vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice","volume":"9","author":"Gabizon","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.xphs.2025.104006_bib0036","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J Control Rel"},{"issue":"3","key":"10.1016\/j.xphs.2025.104006_bib0037","article-title":"A small sugar molecule with huge potential in targeted cancer therapy","volume":"15","author":"Pastuch-Gawo\u0142ek","year":"2023","journal-title":"Pharm [Internet]"},{"issue":"6","key":"10.1016\/j.xphs.2025.104006_bib0038","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1039\/c3sc22205e","article-title":"Glucose conjugation for the specific targeting and treatment of cancer","volume":"4","author":"Calvaresi","year":"2013","journal-title":"Chem Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:28:01Z","timestamp":1766525281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925004605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022354925004605"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104006","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and evaluation of gluconic acid-targeted liposomal doxorubicin for enhanced anti-tumor activity in colon cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104006"}}